Clinical Edge Journal Scan

No causal association between PsA and the genetic risk for skin cancer


 

Key clinical point: This Mendelian randomization (MR) analysis established that there exists no causal association between psoriatic arthritis (PsA) and the genetic risk for skin cancer.

Major finding: PsA did not increase the genetic susceptibility to cutaneous squamous cell carcinoma (odds ratio [OR] 1.00; P = .214) and cutaneous melanoma (OR 1.00; P = .477). Although PsA decreased the genetic risk for basal cell carcinoma (OR 0.94; P = .016), the association disappeared when skin cancer risk factors like skin tanning, radiation-related disorders, and telomere length were considered.

Study details: Findings are from a multivariate MR analysis including 3186 patients with PsA and 240,862 control individuals without PsA.

Disclosures: This study was supported by the Natural Science Foundation of China and the Youth Science Foundation of Xiangya Hospital. The authors declared no conflicts of interest.

Source: Yu N et al. Multivariate Mendelian randomization provides no evidence for causal associations among both psoriasis and psoriatic arthritis, and skin cancer. Front Immunol. 2023;14:1252720 (Sep 19). doi: 10.3389/fimmu.2023.1252720

Recommended Reading

Pilot study: High-dose IL-23 inhibition shows promise for psoriasis remission in some patients
MDedge Rheumatology
FDA approves bimekizumab for moderate to severe plaque psoriasis in adults
MDedge Rheumatology
Bimekizumab offers sustained clinical response in bDMARD-naive PsA patients
MDedge Rheumatology
IL-17 and IL-23(p19) inhibitors as effective as TNF inhibitors in PsA
MDedge Rheumatology
Factors affecting clinical response to fecal microbial transplantation in PsA
MDedge Rheumatology
IL-23 inhibitors effective and safe for PsA patients in real-world settings
MDedge Rheumatology
Preliminary results of a real-world study confirm the efficacy and safety of upadacitinib in PsA
MDedge Rheumatology
Durable improvement in axial symptoms with guselkumab in PsA
MDedge Rheumatology
What factors are responsible for a delayed diagnosis of PsA?
MDedge Rheumatology
Identifying characteristics of difficult-to-treat PsA in real-world conditions
MDedge Rheumatology